Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746633 | 0.91 | — | — | |
| SCHEMBL9199990 | 0.85 | KMT2A (0.37) | EPHX2MEN1KMT2ACA14CA1 | |
| SCHEMBL3485766 | 0.85 | EPHX2 (0.40) | EPHX2MLYCDMEN1KMT2ACA14 | |
| SCHEMBL12712260 | 0.84 | CYP2C9 (0.39) | EPHX2MLYCDMEN1KMT2ACA14 | |
| SCHEMBL18760239 | 0.82 | MAOA (0.33) | MAOAMAOB | |
| SCHEMBL12791479 | 0.82 | KMT2A (0.50) | EPHX2MEN1KMT2ATOP2ACA14 | |
| SCHEMBL12847692 | 0.82 | KMT2A (0.50) | EPHX2MEN1KMT2ATOP2ACA14 | |
| SCHEMBL7862774 | 0.80 | KMT2A (0.48) | EPHX2MEN1KMT2ATOP2ACA14 | |
| SCHEMBL12847852 | 0.80 | KMT2A (0.48) | EPHX2MEN1KMT2ATOP2ACA14 | |
| SCHEMBL7745466 | 0.80 | NR1D1 (0.34) | EPHX2MEN1KMT2ACA14CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266954-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | Draximage, Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266953-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | Draximage, Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| US-7238339-B2 | Bifunctional chelating compounds containing hydroxamic acid residues | DRAXIS SPECIALTY PHARMACEUTICALS INC. (CA) | 2007-07-03 | — | — | US | disclosed |
| US-20040086460-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | JUBILANT DRAXIMAGE INC. (CA) | 2004-05-06 | — | — | US | disclosed |
| US-6623721-B2 | Conjugates can be complexed to a radioisotope metallic element and used for diagnosing or treating receptor-positive tumors | DRAXIMAGE, INC. (CA) | 2003-09-23 | — | — | US | disclosed |
| US-20020076377-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | JUBILANT DRAXIMAGE INC. (CA) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020076377-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | EPRS1, HAMP, PHPT1 | EPHX2 2676/4885MLYCD 1740/4885MEN1 2108/4885 |
| US-20040086460-A1 | Novel bifunctional chelating compounds containing hydroxamic acid residues | EPRS1, HAMP, PHPT1 | EPHX2 2676/4885MLYCD 1740/4885MEN1 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.